Research

Calabrese et al. (2025) reported long-term real-world effectiveness of anakinra and canakinumab in 28 SchS patients (37 treatment lines) from the international AIDA Network registry. Complete response rates were 73.1% (anakinra) and 66.8% (canakinumab). Drug retention at 60 months was 64.7%. Elevated IgG M-protein and lymphadenopathy independently predicted treatment discontinuation.

Schnitzler Syndrome →

significantnew research2026-03-27

Neutrophils identified as predominant IL-1β source in SchS skin

Kambe et al. (2025) demonstrated that neutrophils are the main IL-1β-expressing cells in Schnitzler syndrome lesional skin and blood, using data from the SCan canakinumab study in Japanese patients. This provides mechanistic insight into why IL-1 blockade is so effective and positions neutrophil-targeted approaches as a research avenue.

Schnitzler Syndrome →

incrementalgenetic finding2026-03-27

Low-level NLRP3 mosaicism extends Schnitzler phenotypic spectrum

Daskalopoulou et al. (2025) detected low-level somatic NLRP3 mosaicism in four patients with chronic urticarial lesions including Schnitzler syndrome cases, extending the phenotypic spectrum of NLRP3-related disorders. Findings support considering NLRP3 inhibitor therapy in select Schnitzler-spectrum patients.

Schnitzler Syndrome →

incrementalnew research2026-03-27

Weekly research monitor: 7 new sources added (2025-2026)

Automated weekly search (2026-03-27) found 7 new publications not previously indexed. New entries include: AIDA Network real-world IL-1 data (K2), VEXAS vs Schnitzler differential markers (K3), neutrophil IL-1β source study (K4), NLRP3 mosaicism in urticarial lesions (K5), canakinumab in anakinra-refractory SchS (K6), paraprotein-negative Schnitzler-like syndrome update (K7), and Schnitzler+RA case (K8). No new clinical trials or preprints found. Baseline quality score: 79.7/100.

Schnitzler Syndrome →

incrementalnew research2025-08-14

Alarmin-targeting biologics in development for CRSwNP

Tezepelumab (anti-TSLP) and itepekimab (anti-IL-33) are in phase 2/3 trials for CRSwNP, targeting upstream epithelial alarmins as a novel therapeutic approach.

Chronic Rhinosinusitis with Nasal Polyps →

mediumclinical trial2025-07-01

Oral NLRP3 inhibitor dapansutrile enters clinical trials for CAPS

Dapansutrile (OLT1177), an oral NLRP3 inhibitor with favorable safety profile, is in Phase 2a clinical trial for CAPS maintenance therapy (NCT04524858), potentially replacing injectable biologics.

Cryopyrin-Associated Periodic Syndromes →

significantnew research2025-05-20

Head-to-head biologic comparison studies beginning

First trials comparing dupilumab, omalizumab, and mepolizumab head-to-head are enrolling, which may finally guide evidence-based biologic selection.

Chronic Rhinosinusitis with Nasal Polyps →

mediumgenetic discovery2025-04-22

Deep sequencing reveals somatic mosaicism in 40% of mutation-negative CAPS children

Melo Gomes et al. (2025) found somatic NLRP3 mosaicism via amplicon-based deep sequencing in 4/10 mutation-negative CAPS pediatric patients, with allele frequencies as low as 1.9% (Front Pediatr).

Cryopyrin-Associated Periodic Syndromes →

significanttreatment update2024-10-15

Benralizumab (anti-IL-5Rα) FDA-approved for CRSwNP (2024)

OSTRO trial led to FDA approval of benralizumab for CRSwNP in 2024, making it the fourth approved biologic. Unique ADCC mechanism achieves near-complete eosinophil depletion.

Chronic Rhinosinusitis with Nasal Polyps →

highmechanism2024-09-18

Constitutive inflammasome activation in CAPS mutants characterized

Molina-López et al. (2024) demonstrated that CAPS-associated NLRP3 variants form constitutively active inflammasomes with basal gasdermin D cleavage, IL-18 release, and pyroptosis, responsive to MCC950 inhibitor (Nat Commun).

Cryopyrin-Associated Periodic Syndromes →

mediumdiagnostic advance2022-11-03

Cryo-sensitive aggregation mechanism explains cold-triggered FCAS

Karasawa et al. (2022) showed CAPS-associated NLRP3 mutants form cryo-sensitive aggregates that scaffold inflammasome activation, providing mechanistic explanation for cold-triggered FCAS episodes (eLife).

Cryopyrin-Associated Periodic Syndromes →

significantgenetic finding

Novel MEFV/F2 gene variants in 748th Schnitzler case

Case report from Hungary identified novel MEFV gene variant c.2084A>G and F2 gene variant. Strengthens pyrin-inflammasome hypothesis.

Schnitzler Syndrome →

incrementaltreatment update

Bortezomib (proteasome inhibitor) case report published

Novel use of bortezomib in a patient without detectable serum IL-1β and absent MYD88 L265P.

Schnitzler Syndrome →

incrementalnew research

First Schnitzler syndrome cases reported from Iran

Aminianfar et al. (2025) reported the first cases from Iran, highlighting challenges without access to IL-1 inhibitors.

Schnitzler Syndrome →

incrementalnew research

First IgA λ-type Schnitzler syndrome case reported

Hiroyasu et al. (2026) reported the first IgA lambda-type case with edema and numbness, expanding the immunoglobulin spectrum beyond IgM and IgG.

Schnitzler Syndrome →

significantnew research

Systematic review questions obligate gammopathy criterion

Zhu et al. (2025) reviewed 18 patients with SS lacking monoclonal gammopathy. 77.8% had absent gammopathy; anakinra achieved 92.9% complete response. Suggests gammopathy may not be obligate for diagnosis.

Schnitzler Syndrome →